PET/MRI of central nervous system: current status and future perspective
Imaging plays an increasingly important role in the early diagnosis, prognosis prediction and therapy response evaluation of central nervous system (CNS) diseases. The newly emerging hybrid positron emission tomography/magnetic resonance imaging (PET/MRI) can perform “one-stop-shop” evaluation, including anatomic, functional, biochemical and metabolic information, even at the molecular level, for personalised diagnoses and treatments of CNS diseases. However, there are still several problems to be resolved, such as appropriate PET detectors, attenuation correction and so on. This review will introduce the basic physical principles of PET/MRI and its potential clinical applications in the CNS. We also provide the future perspectives for this field.
• PET/MRI can simultaneously provide anatomic, functional, biochemical and metabolic information.
• PET/MRI has promising potential in various central nervous system diseases.
• Research on the future implementation of PET/MRI is challenging and encouraging.
KeywordsPET/MRI Neurodegenerative diseases Brain tumour Epilepsy Stroke
Central nervous system
Magnetic resonance imaging
Positron emission tomography
Positron emission tomography/computed tomography
Positron emission tomography/magnetic resonance imaging
Standard uptake values
The scientific guarantor of this publication is Long Jiang Zhang. The authors of this manuscript declare relationships with the following companies: UJS is a consultant for and receives research support from Bayer, Bracco, GE, Medrad and Siemens. The other authors have no conflicts of interest to declare. This study was supported by grants from the National Natural Science Foundation of China (grant nos. 81322020, 81230032 and 81171313 to L.J.Z.) and the Program for New Century Excellent Talents in the University (NCET-12-0260 to L.J.Z.). No complex statistical methods were necessary for this paper. Institutional Review Board approval was not obtained because this is a review paper. Written informed consent was not obtained because this is a review paper.
None of the study subjects or cohorts have been previously reported.
Methodology: performed at one institution.
- 1.Global Burden of Disease Study 2013 Collaborators (2015) Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386:743–800CrossRefPubMedCentralGoogle Scholar
- 27.Zhang LJ, Wen J, Liang X et al (2015) Brain default mode network changes after renal transplantation: a diffusion-tensor imaging and resting-state functional MR imaging study. RadiologyGoogle Scholar
- 28.Luo S, Qi RF, Wen JQ et al (2016) Abnormal intrinsic brain activity patterns in patients with end-stage renal disease undergoing peritoneal dialysis: a resting-state functional MR imaging study. Radiology 278:181–189Google Scholar
- 34.Binnewijzend MA, Benedictus MR, Kuijer JP et al (2015) Cerebral perfusion in the predementia stages of Alzheimer's disease. Eur RadiolGoogle Scholar
- 58.Kickingereder P, Radbruch A, Burth S et al (2015) MR perfusion-derived hemodynamic parametric response mapping of bevacizumab efficacy in recurrent glioblastoma. RadiologyGoogle Scholar
- 72.Banaszek A, Bladowska J, Pokryszko-Dragan A et al (2015) Evaluation of the degradation of the selected projectile, commissural and association white matter tracts within normal appearing white matter in patients with multiple sclerosis using diffusion tensor MR imaging–a preliminary study. Pol J Radiol 80:457–463CrossRefPubMedPubMedCentralGoogle Scholar
- 73.Gracien RM, Reitz SC, Hof SM et al (2015) Changes and variability of proton density and T1 relaxation times in early multiple sclerosis: MRI markers of neuronal damage in the cerebral cortex. Eur RadiolGoogle Scholar
- 74.Saake M, Langner S, Schwenke C (2015) MRI in multiple sclerosis: an intra-individual, randomized and multicentric comparison of gadobutrol with gadoterate meglumine at 3 T. Eur RadiolGoogle Scholar